View Author
cancer plasminogen activator tumor patient inhibitor urokinase-type plasminogen activator level pai ‑1 breast expression tissue prognostic biomarker urokinase-type study carcinoma survival breast cancer plasminogen activator inhibitor urokinase metastasi therapy pai ‑1 levels cell carcinoma trial receptor protein system urokinase plasminogen activator cancer patients cancer res disease upa levels pai ‑1 expression utility marker treatment prognosis . cancer stage invasion cancer biomarkers factor phase association colorectal anticancer res . oncol value cancer biomarker breast cancer patients oncol schmitt outcome review plasminogen activation system prognostic impact prognostic factor impact progression relevance analysis . clin status chemotherapy pancreatic activity schmitt m activation anticancer disease recurrence target tumor tissue prognostic relevance expert glioma plasma significance mengele
2 Most Recent Publications
|
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
(Article)
Schmitt, M. Mengele, K. Napieralski, R. Magdolen, V. Reuning, U. Gkazepis, A. Sweep, F.C. Brünner, N. Foekens, J.A. Harbeck, N. |
2010-11-01
|
|
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers
(Article)
Schmitt, M. Mengele, K. Schueren, E. Sweep, F.C. Foekens, J.A. Brünner, N. Laabs, J. Malik, A. Harbeck, N. |
2007-03-01
|
